Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jan. 31, 2021 | Mar. 16, 2021 | |
Details | ||
Registrant CIK | 0001440153 | |
Fiscal Year End | --07-31 | |
Registrant Name | BAKHU HOLDINGS, CORP. | |
SEC Form | 10-Q | |
Period End date | Jan. 31, 2021 | |
Tax Identification Number (TIN) | 26-0510649 | |
Number of common stock shares outstanding | 300,114,000 | |
Filer Category | Non-accelerated Filer | |
Current with reporting | Yes | |
Interactive Data Current | Yes | |
Shell Company | false | |
Small Business | true | |
Emerging Growth Company | false | |
Document Quarterly Report | true | |
Entity File Number | 000-55862 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | One World Trade Center | |
Entity Address, Address Line Two | Suite 130 | |
Entity Address, City or Town | Long Beach | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 90831 | |
Entity Address, Address Description | Address of principal executive offices | |
City Area Code | 858 | |
Local Phone Number | 682-2548 | |
Phone Fax Number Description | Registrant's telephone number | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q2 | |
Document Transition Report | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jan. 31, 2021 | Jul. 31, 2020 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 6,187 | $ 19,754 |
Total Current Assets | 6,187 | 19,754 |
TOTAL ASSETS | 6,187 | 19,754 |
CURRENT LIABILITIES | ||
Accounts payable | 38,154 | 50,404 |
Accrued interest | 32,288 | 14,736 |
Notes payable - related parties | 818,278 | 374,278 |
Total Current Liabilities | 888,720 | 439,418 |
TOTAL LIABILITIES | 888,720 | 439,418 |
STOCKHOLDERS' EQUITY (DEFICIT) | ||
Preferred shares | 0 | 0 |
Common shares | 300,114 | 300,114 |
Additional paid-in capital | 16,536,814 | 15,004,900 |
Accumulated deficit | (17,719,461) | (15,724,678) |
Total Stockholders' Equity (Deficit) | (882,533) | (419,664) |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 6,187 | $ 19,754 |
Consolidated Balance Sheets - P
Consolidated Balance Sheets - Parenthetical - $ / shares | Jan. 31, 2021 | Jul. 31, 2020 |
Details | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Preferred Stock, Shares Authorized | 50,000,000 | 50,000,000 |
Preferred Stock, Shares Issued | 4 | 4 |
Preferred Stock, Shares Outstanding | 4 | 4 |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 500,000,000 | 500,000,000 |
Common Stock, Shares, Issued | 300,114,000 | 300,114,000 |
Common Stock, Shares, Outstanding | 300,114,000 | 300,114,000 |
Consolidated Statement of Opera
Consolidated Statement of Operations - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jan. 31, 2021 | Jan. 31, 2020 | Jan. 31, 2021 | Jan. 31, 2020 | |
Details | ||||
NET REVENUES | $ 0 | $ 0 | $ 0 | $ 0 |
OPERATING EXPENSES | ||||
Consulting fees | 786,898 | 3,414 | 1,721,002 | 6,085 |
Professional fees | 53,528 | 53,372 | 151,103 | 82,035 |
Selling, general and administrative | 82,395 | 13,652 | 104,980 | 14,625 |
Total Operating Expenses | 922,821 | 70,438 | 1,977,085 | 102,745 |
LOSS FROM OPERATIONS | (922,821) | (70,438) | (1,977,085) | (102,745) |
OTHER INCOME (EXPENSES) | ||||
Interest expense | (11,108) | (3,043) | (17,698) | (5,468) |
Total Other Income (Expenses) | (11,108) | (3,043) | (17,698) | (5,468) |
LOSS BEFORE INCOME TAXES | (933,929) | (73,481) | (1,994,783) | (108,213) |
PROVISION FOR INCOME TAXES | 0 | 0 | 0 | 0 |
NET LOSS | $ (933,929) | $ (73,481) | $ (1,994,783) | $ (108,213) |
BASIC NET LOSS PER SHARE | $ 0 | $ 0 | $ (0.01) | $ 0 |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | 300,114,000 | 288,938,184 | 300,114,000 | 288,938,184 |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' Deficit - USD ($) | Total | Preferred Stock | Common Stock | Additional Paid-in Capital | Retained Earnings | Noncontrolling Interest |
Stockholders' Equity Attributable to Parent, Beginning Balance at Jul. 31, 2019 | $ 0 | $ 288,938 | $ 14,177,986 | $ (14,618,012) | $ (151,088) | |
Shares, Outstanding, Beginning Balance at Jul. 31, 2019 | 4 | 288,938,184 | ||||
Net Income (Loss) | $ 0 | $ 0 | 0 | (34,732) | (34,732) | |
Stockholders' Equity Attributable to Parent, Ending Balance at Oct. 31, 2019 | $ 0 | $ 288,938 | 14,177,986 | (14,652,744) | (185,820) | |
Shares, Outstanding, Ending Balance at Oct. 31, 2019 | 4 | 288,938,184 | ||||
Stockholders' Equity Attributable to Parent, Beginning Balance at Jul. 31, 2019 | $ 0 | $ 288,938 | 14,177,986 | (14,618,012) | (151,088) | |
Shares, Outstanding, Beginning Balance at Jul. 31, 2019 | 4 | 288,938,184 | ||||
Net Income (Loss) | $ (108,213) | |||||
Stockholders' Equity Attributable to Parent, Ending Balance at Jan. 31, 2020 | $ 0 | $ 288,938 | 14,177,986 | (14,726,225) | (259,301) | |
Shares, Outstanding, Ending Balance at Jan. 31, 2020 | 4 | 288,938,184 | ||||
Stockholders' Equity Attributable to Parent, Beginning Balance at Oct. 31, 2019 | $ 0 | $ 288,938 | 14,177,986 | (14,652,744) | (185,820) | |
Shares, Outstanding, Beginning Balance at Oct. 31, 2019 | 4 | 288,938,184 | ||||
Net Income (Loss) | (73,481) | $ 0 | $ 0 | 0 | (73,481) | (73,481) |
Stockholders' Equity Attributable to Parent, Ending Balance at Jan. 31, 2020 | $ 0 | $ 288,938 | 14,177,986 | (14,726,225) | (259,301) | |
Shares, Outstanding, Ending Balance at Jan. 31, 2020 | 4 | 288,938,184 | ||||
Stockholders' Equity Attributable to Parent, Beginning Balance at Jul. 31, 2020 | (419,664) | $ 0 | $ 300,114 | 15,004,900 | (15,724,678) | (419,664) |
Shares, Outstanding, Beginning Balance at Jul. 31, 2020 | 4 | 300,114,000 | ||||
Net Income (Loss) | $ 0 | $ 0 | 0 | (1,060,854) | (1,060,854) | |
Stockholders' Equity Attributable to Parent, Ending Balance at Oct. 31, 2020 | $ 0 | $ 300,114 | 15,880,279 | (16,785,532) | (605,139) | |
Shares, Outstanding, Ending Balance at Oct. 31, 2020 | 4 | 300,114,000 | ||||
Issuance of stock options | $ 0 | $ 0 | 875,379 | 0 | 875,379 | |
Stockholders' Equity Attributable to Parent, Beginning Balance at Jul. 31, 2020 | (419,664) | $ 0 | $ 300,114 | 15,004,900 | (15,724,678) | (419,664) |
Shares, Outstanding, Beginning Balance at Jul. 31, 2020 | 4 | 300,114,000 | ||||
Net Income (Loss) | (1,994,783) | |||||
Stockholders' Equity Attributable to Parent, Ending Balance at Jan. 31, 2021 | (882,533) | $ 0 | $ 300,114 | 16,536,814 | (17,719,461) | (882,533) |
Shares, Outstanding, Ending Balance at Jan. 31, 2021 | 4 | 300,114,000 | ||||
Stockholders' Equity Attributable to Parent, Beginning Balance at Oct. 31, 2020 | $ 0 | $ 300,114 | 15,880,279 | (16,785,532) | (605,139) | |
Shares, Outstanding, Beginning Balance at Oct. 31, 2020 | 4 | 300,114,000 | ||||
Net Income (Loss) | (933,929) | $ 0 | $ 0 | 0 | (933,929) | (933,929) |
Stockholders' Equity Attributable to Parent, Ending Balance at Jan. 31, 2021 | $ (882,533) | $ 0 | $ 300,114 | 16,536,814 | (17,719,461) | (882,533) |
Shares, Outstanding, Ending Balance at Jan. 31, 2021 | 4 | 300,114,000 | ||||
Issuance of stock options | $ 0 | $ 0 | $ 656,535 | $ 0 | $ 656,535 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 6 Months Ended | |
Jan. 31, 2021 | Jan. 31, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net Income (Loss) | $ (1,994,783) | $ (108,213) |
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities | ||
Stock based compensation | 1,531,914 | 0 |
Changes in operating assets and liabilities: | ||
Accounts payable | (12,250) | 20,057 |
Accrued liabilities | 17,552 | 5,468 |
Net Cash Used by Operating Activities | (457,567) | (82,688) |
CASH FLOWS FROM INVESTING ACTIVITIES | 0 | 0 |
Net Cash Provided by (Used in) Financing Activities | ||
Payments on notes payable - related parties | (2,000) | 0 |
Proceeds from notes payable - related parties | 446,000 | 82,500 |
Net Cash Provided by Financing Activities | 444,000 | 82,500 |
DECREASE IN CASH AND CASH EQUIVALENTS | (13,567) | (188) |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 19,754 | 1,633 |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 6,187 | 1,445 |
SUPPLEMENTAL DISCLOSURES: | ||
Interest Paid, Including Capitalized Interest, Operating and Investing Activities | 0 | 0 |
Income Taxes Paid, Net | 0 | 0 |
Non-cash financing activity: | ||
term borrowings - related parties | $ 0 | $ 147,513 |
NOTE 1 - ORGANIZATION AND BUSIN
NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS; BASIS OF PRESENTATION | 6 Months Ended |
Jan. 31, 2021 | |
Notes | |
NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS; BASIS OF PRESENTATION | N OTE 1 - ORGANIZATION AND BUSINESS OPERATIONS; BASIS OF PRESENTATION The Company was incorporated under the laws of the State of Nevada, on April 24, 2008 under the name Planet Resources, Corp. In May 2009, the Company also began to look for other types of business to pursue that would benefit the shareholders. In order to pursue businesses that may not be in the mining industry the name of the Company was changed with the approval of the Directors and Shareholders to Bakhu Holdings, Corp. on May 4, 2009 (“Bakhu, or the “Company”). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. For the period from inception, April 24, 2008 through January 31, 2021 the Company has accumulated losses of $17,719,461. On August 9, 2019, the Company formed Cell Science CBD International, Inc., a California corporation as a wholly owned subsidiary. On November 26, 2019, the name of the subsidiary was changed to CBD Biotech, Inc., (“CBD”). On January 5, 2020, the Company entered into a Sublicense Agreement with CBD wherein the Company granted a sublicense of the Licensed Science as it relates to the production and manufacturing of cannabis and their byproducts which have measurable tetrahydrocannabinol (THC) concentration potency less than 3% on a dry weight basis. CBD had no active operations as of January 31, 2021. In the opinion of management, the Company’s financial statements reflect all adjustments that are of a normal recurring nature necessary for presentation of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with the instructions to Form 10-Q in Article 10 of SEC Regulation S-X. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. As used in this report, the term the “Company” means Bakhu Holdings Corp. and its subsidiary, unless the context indicates otherwise. The Company condensed or omitted certain information and footnote disclosures normally included in our annual audited financial statements, which the Company prepared in accordance with GAAP. Our interim financial statements should be read in conjunction with our annual report on Form 10-K for the year ended July 31, 2020, and our quarterly reports on Form 10-Q for the quarters ended October 31, 2020. |
NOTE 2 - SUMMARY OF SIGNIFICANT
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Jan. 31, 2021 | |
Notes | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. Going Concern The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of $17,719,461 as of January 31, 2021 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Use of Estimates and Assumptions The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Foreign Currency Translation The Company’s functional currency and its reporting currency is the United States dollar. Financial Instruments The carrying value of the Company’s financial instruments approximates their fair value because of the short maturity of these instruments. Stock-based Compensation At January 31, 2021, the Company had one stock-based compensation plan, the 2020 Long-Term Incentive Plan (“2020 Plan”), which is more fully described in Note 3. On September 22, 2020, the Company granted to each of its directors, Thomas K. Emmitt, Peter Whitton, Aristole Popolizio and Evripides Drakos, a non-qualified stock option to purchase 300,000 shares of common stock, for a total of 1,200,000 shares, at an exercise price of $5.10 per share, representing the current price at which the Company is offering and selling its restricted shares for cash in its capital raising efforts. Such Options shall be exercisable for a period of seven years. Twenty percent (20%) (i.e. 60,000) of the options shall vest and be exercisable immediately with the remaining 240,000 options vesting at the rate of 1/12 (i.e. 20,000 shares) per month so that all options shall be fully vested and exercisable on the first anniversary of the Grant Date. The fair value of each option grant issued under the 2020 Plan was estimated using the Black-Scholes option pricing model. Assumptions used to estimate the fair value of options granted include (1) stock price of $5.10 per share, (2) exercise price of $5.10 per share, (3) expected life of 1 year, (4) expected volatility of 146.49% and (5) risk free interest rate of 0.12%. Based on the above assumptions, the Company recognized stock-based compensation of $1,531,914 which is included in Consulting fees on the Statement of Operations for the six months ended January 31, 2021. As of January 31, 2021, there was $1,750,759 of total unrecognized stock-based compensation that is expected to be recognized over the 1-year vesting period. Income Taxes Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Basic and Diluted Net Loss per Share The Company computes net loss per share in accordance with ASC 105, “Earnings per Share.” ASC 105 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all potentially dilutive common shares outstanding during the period. Diluted EPS excludes all potentially dilutive shares if their effect is anti-dilutive. Professional fees Substantially all professional fees presented in the financial statements represent accounting fees, audit fees and legal fees associated with the filing of reports with the Securities and Exchange Commission. Also included in professional fees are fees paid to the stock transfer agent. The fees are expensed as incurred. Fiscal Periods The Company’s fiscal year end is July 31. Recently Issued Accounting Pronouncements The Company has reviewed accounting pronouncements issued during the past two years and have adopted any that are applicable to the Company. The Company has determined that none had a material impact on our financial position, results of operations, or cash flows for the periods presented in this report. |
NOTE 3 - PREFERRED AND COMMON S
NOTE 3 - PREFERRED AND COMMON STOCK | 6 Months Ended |
Jan. 31, 2021 | |
Notes | |
NOTE 3 - PREFERRED AND COMMON STOCK | NOTE 3 - PREFERRED AND COMMON STOCK On August 8, 2018, the Board of Directors of the Company approved the amendment and restatement of the Company’s Articles of Incorporation. The purpose of the amendment and restatement of the Articles of Incorporation was to: (i) Increase the number of authorized shares of Common Stock to 500,000,000; (ii) Increase the number of authorized shares of Preferred Stock to 50,000,000; (iii) Grant the Board of Directors the rights to designate classes of preferred stock, and to define the powers, preferences, rights, and restrictions thereof; The preferred and common stock has a par value of $0.001 per share. On August 8, 2018, the Company issued 4 shares of Series A Preferred Stock to the Company’s controlling shareholder, The OZ Corporation, a California corporation. On December 20, 2018, the Company entered into a License Agreement with Cell Science, Ltd. (CSH”). Pursuant to the License Agreement, the Company is being granted an exclusive license by CSH with respect to certain patents and intellectual property for the production of phytocannabinoids for use in medical treatments and in exchange for 210,000,000 shares of common stock of the Company. On February 14, 2019, the stock was issued and recorded as consulting fees valued at $10,500,000. On April 7, 2019, the Company issued 7,000,000 shares of common stock for the conversion of convertible notes payable and accrued interest in the amount of $10,199. NOTE 3 - PREFERRED AND COMMON STOCK (continued) On March 9, 2020, the Company issued 11,061,816 restricted shares of Common Stock to the OZ Corporation, in consideration of ongoing consulting and advisory services provided to the Company, on terms as previously agreed to the Company and the OZ Corporation. The securities were issued pursuant to an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933. The OZ Corporation is intimately acquainted with the Company’s business plan and proposed activities at the time of issuance and possessed information on the Company necessary to make an informed investment decision. The estimated fair value of the stock was $99,556 and has been expensed and included in “Consulting fees” in the three and six months ended April 30, 2020. Stock Option Plan On September 22, 2020, the board of directors adopted the 2020 Long-Term Incentive Plan (“2020 Plan”), under which 20,000,000 shares of our common stock were reserved for issuance by us to attract and retain employees and directors and to provide such persons with incentives and awards for superior performance and providing services to us. The 2020 Plan is administered by a committee comprised of our board of directors or appointed by the board of directors, which has broad flexibility in designing stock-based incentives. The board of directors determines the number of shares granted and the option exercise price pursuant to the 2020 Plan. The following table summarizes the stock option award activity under the 2020 Plan during the six months ended January 31, 2021: Number of options Outstanding at July 31, 2020 - Granted 1,200,000 Exercised - Forfeited - Outstanding at January 31, 2021 1,200,000 See Stock-based Compensation under Note 2 for description of options granted. |
NOTE 4 - INCOME TAXES
NOTE 4 - INCOME TAXES | 6 Months Ended |
Jan. 31, 2021 | |
Notes | |
NOTE 4 - INCOME TAXES | NOTE 4 - INCOME TAXES As of January 31, 2021, the Company had net operating loss carry forwards that may be available to reduce future years’ taxable income through 2030. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. |
NOTE 5 - RELATED PARTY TRANSACT
NOTE 5 - RELATED PARTY TRANSACTIONS | 6 Months Ended |
Jan. 31, 2021 | |
Notes | |
NOTE 5 - RELATED PARTY TRANSACTIONS | NOTE 5 - NOTES PAYABLE – RELATED PARTIES On August 1, 2019, the Company executed a promissory note in favor of Company’s controlling shareholder, The OZ Corporation, to evidence monies loan to the Company from December 26, 2018 through July 31, 2019 in the amount of $147,513, and to evidence any additional amounts that may be loaned to the Company thereafter. Pursuant to the terms of the promissory note, the principal and unpaid accrued simple interest at the rate of 6.0% per annum shall be due and payable on or before December 31, 2019. The promissory note also provides that the Company may extend the maturity date for an additional 12 months, until December 31, 2020, by paying an extension fee of 1.00% of the outstanding principal loan balance, which may at the lenders’ option be advanced and added to the then outstanding principal balance. The principal amount of the promissory note shall be increased by the amount of any additional advances of funds made by The OZ Corporation to the Company, from time to time, from the date of such advance. Under the terms of the promissory note, The OZ Corporation, at its option may, at any time, convert all or any portion of the then unpaid principal balance and any unpaid accrued interest into shares of the Company’s common stock. The number of shares of common stock to be issued upon such conversion shall be equal to the quotient obtained by dividing (i) the then unpaid principal balance and any unpaid accrued interest of NOTE 5 - NOTES PAYABLE – RELATED PARTIES (continued) the promissory note being converted by (ii) 80% of the average closing price of the common stock of the Company, for the ninety (90) trading days before the conversion date, rounded up to the nearest whole share. The principal balance and accrued interest due on the note was $818,278 and $32,288, respectively as of January 31, 2021. The Company did not assign any value to the conversion feature of the Note because the 80% of the common stock of the Company had a negative book value of as of January 31, 2021 and continues to have a negative book value. Furthermore, the company has not generated any revenue to date. |
NOTE 6 - COMMITMENTS AND CONTIN
NOTE 6 - COMMITMENTS AND CONTINGENCIES | 6 Months Ended |
Jan. 31, 2021 | |
Notes | |
NOTE 6 - COMMITMENTS AND CONTINGENCIES | NOTE 6 - COMMITMENTS AND CONTINGENCIES. Under the April 2020 strategic alliance agreement and related sublicense between the Company’s subsidiary, CBD Biotech, Inc., and Integrity Cannabis Solutions, Inc. (“ICS”), the Company is obligated to issue to ICS that number of shares of Bakhu common stock equal to 0.5% of the number of shares outstanding as of the date that the production facility of ICS is completed and commences production. Further, if the sublicense is terminated, CBD Biotech will be obligated to repay to ICS its initial $250,000 license fee and reimburse ICS for the cost of the laboratory operational equipment used in its production facility, which thereafter will be owned and managed jointly by ICS and CBD Biotech. |
NOTE 7 - SUBSEQUENT EVENTS
NOTE 7 - SUBSEQUENT EVENTS | 6 Months Ended |
Jan. 31, 2021 | |
Notes | |
NOTE 7 - SUBSEQUENT EVENTS | NOTE 7 – SUBSEQUENT EVENTS The Company has evaluated subsequent events for the period of January 31, 2021 through the date the financial statements were issued and concluded there were no items that required recognition or disclosure in its financial statements. |
NOTE 2 - SUMMARY OF SIGNIFICA_2
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Basis of Presentation | Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. |
NOTE 2 - SUMMARY OF SIGNIFICA_3
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Going Concern | Going Concern The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of $17,719,461 as of January 31, 2021 and further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern. |
NOTE 2 - SUMMARY OF SIGNIFICA_4
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. |
NOTE 2 - SUMMARY OF SIGNIFICA_5
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates and Assumptions (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Use of Estimates and Assumptions | Use of Estimates and Assumptions The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
NOTE 2 - SUMMARY OF SIGNIFICA_6
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Foreign Currency Translation | Foreign Currency Translation The Company’s functional currency and its reporting currency is the United States dollar. |
NOTE 2 - SUMMARY OF SIGNIFICA_7
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Financial Instruments (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Financial Instruments | Financial Instruments The carrying value of the Company’s financial instruments approximates their fair value because of the short maturity of these instruments. |
NOTE 2 - SUMMARY OF SIGNIFICA_8
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Stock-based Compensation | Stock-based Compensation At January 31, 2021, the Company had one stock-based compensation plan, the 2020 Long-Term Incentive Plan (“2020 Plan”), which is more fully described in Note 3. On September 22, 2020, the Company granted to each of its directors, Thomas K. Emmitt, Peter Whitton, Aristole Popolizio and Evripides Drakos, a non-qualified stock option to purchase 300,000 shares of common stock, for a total of 1,200,000 shares, at an exercise price of $5.10 per share, representing the current price at which the Company is offering and selling its restricted shares for cash in its capital raising efforts. Such Options shall be exercisable for a period of seven years. Twenty percent (20%) (i.e. 60,000) of the options shall vest and be exercisable immediately with the remaining 240,000 options vesting at the rate of 1/12 (i.e. 20,000 shares) per month so that all options shall be fully vested and exercisable on the first anniversary of the Grant Date. The fair value of each option grant issued under the 2020 Plan was estimated using the Black-Scholes option pricing model. Assumptions used to estimate the fair value of options granted include (1) stock price of $5.10 per share, (2) exercise price of $5.10 per share, (3) expected life of 1 year, (4) expected volatility of 146.49% and (5) risk free interest rate of 0.12%. Based on the above assumptions, the Company recognized stock-based compensation of $1,531,914 which is included in Consulting fees on the Statement of Operations for the six months ended January 31, 2021. As of January 31, 2021, there was $1,750,759 of total unrecognized stock-based compensation that is expected to be recognized over the 1-year vesting period. |
NOTE 2 - SUMMARY OF SIGNIFICA_9
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Income Taxes | Income Taxes Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. |
NOTE 2 - SUMMARY OF SIGNIFIC_10
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basic and Diluted Net Loss per Share (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Basic and Diluted Net Loss per Share | Basic and Diluted Net Loss per Share The Company computes net loss per share in accordance with ASC 105, “Earnings per Share.” ASC 105 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all potentially dilutive common shares outstanding during the period. Diluted EPS excludes all potentially dilutive shares if their effect is anti-dilutive. |
NOTE 2 - SUMMARY OF SIGNIFIC_11
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Professional fees (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Professional fees | Professional fees Substantially all professional fees presented in the financial statements represent accounting fees, audit fees and legal fees associated with the filing of reports with the Securities and Exchange Commission. Also included in professional fees are fees paid to the stock transfer agent. The fees are expensed as incurred. |
NOTE 2 - SUMMARY OF SIGNIFIC_12
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fiscal Periods (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Fiscal Periods | Fiscal Periods The Company’s fiscal year end is July 31. |
NOTE 2 - SUMMARY OF SIGNIFIC_13
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recently Issued Accounting Pronouncements (Policies) | 6 Months Ended |
Jan. 31, 2021 | |
Policies | |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements The Company has reviewed accounting pronouncements issued during the past two years and have adopted any that are applicable to the Company. The Company has determined that none had a material impact on our financial position, results of operations, or cash flows for the periods presented in this report. |
NOTE 3 - PREFERRED AND COMMON_2
NOTE 3 - PREFERRED AND COMMON STOCK: Share-based Payment Arrangement, Option, Activity (Tables) | 6 Months Ended |
Jan. 31, 2021 | |
Tables/Schedules | |
Share-based Payment Arrangement, Option, Activity | Number of options Outstanding at July 31, 2020 - Granted 1,200,000 Exercised - Forfeited - Outstanding at January 31, 2021 1,200,000 |
NOTE 1 - ORGANIZATION AND BUS_2
NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS; BASIS OF PRESENTATION (Details) - USD ($) | 6 Months Ended | |
Jan. 31, 2021 | Jul. 31, 2020 | |
Details | ||
Entity Incorporation, State or Country Code | NV | |
Entity Incorporation, Date of Incorporation | Apr. 24, 2008 | |
Accumulated deficit | $ 17,719,461 | $ 15,724,678 |
NOTE 2 - SUMMARY OF SIGNIFIC_14
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) - USD ($) | Jan. 31, 2021 | Jul. 31, 2020 |
Details | ||
Accumulated deficit | $ 17,719,461 | $ 15,724,678 |
NOTE 2 - SUMMARY OF SIGNIFIC_15
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Details) - USD ($) | 6 Months Ended | |
Jan. 31, 2021 | Jan. 31, 2020 | |
Details | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | 1,200,000 | |
Stock based compensation | $ 1,531,914 | $ 0 |
Unrecognized stock-based compensation to be recognized over the 1-year vesting period | $ 1,750,759 |
NOTE 3 - PREFERRED AND COMMON_3
NOTE 3 - PREFERRED AND COMMON STOCK (Details) - USD ($) | Apr. 01, 2019 | Mar. 09, 2019 | Dec. 20, 2018 | Jan. 31, 2021 | Jan. 31, 2020 | Jan. 31, 2021 | Jan. 31, 2020 | Sep. 22, 2020 | Jul. 31, 2020 | Feb. 14, 2019 | Aug. 08, 2018 |
Common Stock, Shares Authorized | 500,000,000 | 500,000,000 | 500,000,000 | ||||||||
Preferred Stock, Shares Authorized | 50,000,000 | 50,000,000 | 50,000,000 | ||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||
Preferred Stock, Shares Issued | 4 | 4 | 4 | ||||||||
Debt Conversion, Converted Instrument, Shares Issued | 7,000,000 | ||||||||||
Debt Conversion, Converted Instrument, Amount | $ 10,199 | ||||||||||
Consulting fees | $ 786,898 | $ 3,414 | $ 1,721,002 | $ 6,085 | |||||||
Common Stock, Capital Shares Reserved for Future Issuance | 20,000,000 | ||||||||||
Cell Science, Ltd | |||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 210,000,000 | ||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $ 10,500,000 | ||||||||||
OZ Corporation | |||||||||||
Preferred Stock, Shares Issued | 4 | ||||||||||
Stock issued under Consulting Agreements, Shares | 11,061,816 | ||||||||||
Consulting fees | $ 99,556 | $ 99,556 |
NOTE 3 - PREFERRED AND COMMON_4
NOTE 3 - PREFERRED AND COMMON STOCK: Share-based Payment Arrangement, Option, Activity (Details) - shares | 6 Months Ended | |
Jan. 31, 2021 | Jul. 31, 2020 | |
Details | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 1,200,000 | 0 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | 1,200,000 |
NOTE 5 - RELATED PARTY TRANSA_2
NOTE 5 - RELATED PARTY TRANSACTIONS (Details) - USD ($) | Aug. 01, 2019 | Jan. 31, 2021 | Jan. 31, 2020 |
term borrowings - related parties | $ 0 | $ 147,513 | |
Notes Payable, Related Parties, Current | 818,278 | ||
Interest Payable, Current | $ 32,288 | ||
OZ Corporation | |||
term borrowings - related parties | $ 147,513 | ||
Debt Instrument, Interest Rate During Period | 6.00% |
NOTE 6 - COMMITMENTS AND CONT_2
NOTE 6 - COMMITMENTS AND CONTINGENCIES (Details) | 6 Months Ended |
Jan. 31, 2021USD ($) | |
Details | |
License Fee | $ 250,000 |